IP Library Granted Patent US 8,198,230
Granted Patent B2
US 8,198,230 · App. 12/930,494 · Granted Jun 12, 2012

Synthetic mimics of mammalian cell surface receptors: method and compositions

Assignee: The Penn State Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,198,230
App. No.
12/930,494
Granted
Jun 12, 2012
Kind
B2
Abstract

The present invention relates to new synthetic receptors. More particularly, the present invention relates to the use of the synthetic receptors for delivering a protein, peptide, drug, prodrug, lipid, nucleic acid, carbohydrate or small molecule into a target cell via receptor-mediated endocytosis. According to the invention, novel synthetic mimics of cell surface receptors have been designed and methods for use of the same are disclosed.

Claims (14)

1. A method of producing a therapeutic effect by delivering a synthetic cell receptor into a cell comprising:

contacting said cell with a synthetic cell receptor that inserts into a cell plasma membrane on a cell surface wherein said receptor comprises:

a target-binding motif, wherein said target-binding motif binds or is covalently linked to a target;

a linker region linking a membrane-binding element with the target-binding motif, wherein said membrane-binding element anchors said receptor into a cell plasma membrane and is a derivative of 3β-cholesterylamine or 3β-dihydrocholesterylamine;

triggering receptor-mediated endocytosis of said receptor;

delivery of said receptor to said cell by an endosome; and

disrupting said endosome by an endosome disrupter to release said target and produce said therapeutic effect.

2. The method of claim 1 further comprising the recycling of said receptor to said cell surface.

3. The method of claim 1 wherein said cells are infected with a pathogen that secretes membrane-disruptive proteins.

4. The method of claim 3 wherein said pathogen is bacterial, viral or a microorganism.

5. The method of claim 1 wherein said target is a member selected from the group consisting of a protein, polypeptide, peptide, antibody, ligand, cytokine, growth factor, immunoglobulin, nucleic acid, lipid, carbohydrate, membrane, prodrug, drug, small molecule or a fragment thereof and combinations of the same.

6. The method of claim 1 wherein said endosome disruptor is a member selected from the group consisting of a peptide, protein, nucleic acid, lipid, polymer, or small molecule, an immunoglobulin or a fragment thereof, hemagglutinin or a fragment or variant thereof, listeriolysin O, GALA, endoporter, poly(alkylacrylic acid) and combinations of the same.

7. The method of claim 1 wherein said endosome disruptor is a small molecule or macromolecule that preferentially disrupts membranes at acidic (endosomal) pH (pH≦7).

8. The method of claim 1 wherein said therapeutic effect is bacteriocidal, bacteriostatic, anticancer, antiviral, or any other biological response.

Assignments (1)
CONFIRMATORY LICENSE Recorded Sep 12, 2011
From: THE PENNSYLVANIA STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026908/0670 →
Continuity (5)
Division 12317473 · Dec 22, 2008
Division 11368661 · Mar 6, 2006
Continuation In Part 11242388 · Oct 3, 2005
Provisional Application 60616391 · Oct 6, 2004
Related Publication 20110236344A1 · Sep 29, 2011